LON:MXCT

MaxCyte Share Forecast, Price & News

GBX 1,075

0.00 (0.00 %)

(As of 08/4/2021 04:38 PM ET)

Add

Compare

Today's Range

1,060

▼

1,100

50-Day Range

890

▼

1,120

52-Week Range

272

▼

1,180

Volume269,977 shs

Average Volume204,645 shs

Market Capitalization£914.28 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive MXCT News and Ratings via Email

Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter.

About MaxCyte

MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.

MaxCyte (LON:MXCT) Reaches New 1-Year High at $1,180.00
August 2, 2021 | americanbankingnews.com

MaxCyte, Inc. - Pricing of Offering and Approval to List on Nasdaq
August 2, 2021 | proactiveinvestors.com.au

MaxCyte, Inc. : Price Monitoring Extension
July 31, 2021 | markets.businessinsider.com

Dole Drops in IPO. 7 Biotechs Went Public, Too.
July 30, 2021 | finance.yahoo.com

DLA Piper advises underwriters of MaxCyte's upsized US IPO
July 30, 2021 | finance.yahoo.com

MoCo biotech MaxCyte sets terms for Nasdaq debut, preps for nine-figure raise
July 26, 2021 | bizjournals.com

MaxCyte Announces Launch of Offering and Application to List on the Nasdaq Global Market
July 26, 2021 | finance.yahoo.com

MaxCyte (LON:MXCT) Reaches New 1-Year High at $1,064.30
July 12, 2021 | americanbankingnews.com

Is MaxCyte (LON:MXCT) Using Debt In A Risky Way?
June 29, 2021 | finance.yahoo.com

MaxCyte, Inc. (MXCT.L)
June 18, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange LON
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
Current SymbolLON:MXCT
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.maxcyte.com
Phone+1-301-9441700
Employees65
Year FoundedN/A

Sales & Book Value

Annual Sales£26.92 million
Price / Sales33.96
Cash FlowGBX 90.79 per share
Price / Cash Flow11.84
Book ValueGBX 96 per share
Price / Book11.20

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares85,049,000
Market Cap£914.28 million
Next Earnings Date9/20/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.41 out of 5 stars

2.5 Analyst's Opinion

Consensus Rating
MaxCyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of GBX 1,240, MaxCyte has a forecasted upside of 15.6% from its current price of GBX 1,073.
Amount of Analyst Coverage
MaxCyte has only been the subject of 1 research reports in the past 90 days.

4.5 Community Rank

Outperform Votes
MaxCyte has received 152 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
MaxCyte has received 69 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
MaxCyte has received 68.78% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about MaxCyte and other stocks. Vote “Outperform” if you believe MXCT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MXCT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
MaxCyte does not currently pay a dividend.
Dividend Growth
MaxCyte does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MaxCyte insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of MaxCyte is -71.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of MaxCyte is -71.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
MaxCyte has a P/B Ratio of 11.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

MaxCyte (LON:MXCT) Frequently Asked Questions

Is MaxCyte a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MaxCyte in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" MaxCyte stock.
View analyst ratings for MaxCyte or view top-rated stocks.

What stocks does MarketBeat like better than MaxCyte?

Wall Street analysts have given MaxCyte a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but MaxCyte wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is MaxCyte's next earnings date?

MaxCyte is scheduled to release its next quarterly earnings announcement on Monday, September 20th 2021.
View our earnings forecast for MaxCyte.

How has MaxCyte's stock been impacted by Coronavirus?

MaxCyte's stock was trading at GBX 150 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MXCT stock has increased by 616.7% and is now trading at GBX 1,075.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for MXCT?

1 brokerages have issued 12-month price objectives for MaxCyte's shares. Their forecasts range from GBX 1,240 to GBX 1,240. On average, they expect MaxCyte's share price to reach GBX 1,240 in the next twelve months. This suggests a possible upside of 15.3% from the stock's current price.
View analysts' price targets for MaxCyte or view top-rated stocks among Wall Street analysts.

Who are MaxCyte's key executives?

MaxCyte's management team includes the following people:

Mr. Douglas Arthur Doerfler, Founder, Pres, CEO & Exec. Director (Age 65, Pay $705.25k)
Mr. Ronald Evan Holtz Ph.D., CPA, Sr. VP, Chief Accounting Officer, Company Sec. & Exec. Director (Age 63, Pay $445.93k)
Ms. Amanda Louise Murphy C.F.A., CFA, Chief Financial Officer
Mr. Maher Masoud, Exec. VP & Gen. Counsel
Mr. Thomas Michael Ross, Exec. VP of Global Sales (Age 60)
Mr. Markus J. Hunkeler, VP of Marketing
Dr. Claudio Dansky Ullmann M.D., Chief Medical Officer
Ms. Shruti Abbato, Exec. VP of Bus. Devel. for CARMA Cellular Therapies

Who are some of MaxCyte's key competitors?

Some companies that are related to MaxCyte include Renalytix AI (RENX), Profound Medical (PRN), Sernova (SVA), Akumin (AKU), Oncimmune (ONC), Verici Dx (VRCI), Profound Medical (PRN), Yourgene Health (YGEN), LexaGene (LXG), SQI Diagnostics (SQD), Cambridge Cognition (COG), VentriPoint Diagnostics (VPT), Abingdon Health (ABDX), genedrive (GDR) and GeneNews (GEN).
View all of MXCT's competitors.

What other stocks do shareholders of MaxCyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MaxCyte investors own include boohoo group (BOO), Juno Therapeutics (JUNO), (ATE), Astrotech (ASTC), Arcturus Therapeutics (ARCT), (AQB), Aptose Biosciences (APTO), Appili Therapeutics (APLIF), Argan (AGX) and Applied Genetic Technologies (AGTC).

What is MaxCyte's stock symbol?

MaxCyte trades on the London Stock Exchange (LON) under the ticker symbol "MXCT."

How do I buy shares of MaxCyte?

Shares of MXCT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is MaxCyte's stock price today?

One share of MXCT stock can currently be purchased for approximately GBX 1,075.

How much money does MaxCyte make?

MaxCyte has a market capitalization of £914.28 million and generates £26.92 million in revenue each year.

How many employees does MaxCyte have?

MaxCyte employs 65 workers across the globe.

What is MaxCyte's official website?

The official website for MaxCyte is www.maxcyte.com.

Where are MaxCyte's headquarters?

MaxCyte is headquartered at 22 Firstfield Rd Ste 110, GAITHERSBURG, MD 20878-1795, United States.

How can I contact MaxCyte?

MaxCyte's mailing address is 22 Firstfield Rd Ste 110, GAITHERSBURG, MD 20878-1795, United States. The company can be reached via phone at +1-301-9441700.

This page was last updated on 8/4/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here